Horizon Discovery declines Abcam’s USD 367 million takeover bid Horizon Discovery has recently rejected a buyout bid worth USD 367 million from Abcam. Horizon Discovery is an expert in ge...
FDA still not completely satisfied with Kamada’s inhaled AAT drug(Synthetic Biologics) Kamada is stuck again with a new obstacle in its way to bring the first inhaled treatment for alpha-1 antitrypsin (AAT) deficiency in the market as an alternative to currently present intravenous drugs. The company specializes in ...
Find MorePositive Phase 1 data supports Cyclacel’s plans for CDK2/9 inhibitor CYC065 Cyclacel faced a big failure in for its late-stage drug for leukemia just a year ago hitting hard on its shares. After that the attention was shifted towards an early-stage CDK inhibitor. As per the latest results presented by the company CD...
Find MoreCellectis successfully bags USD 164 million for Gene-editing and CAR-T programs After a rough journey in 2017, the road seems clear for French CAR-T specialist Cellectis, which has recently closed a USD 164 million U.S. public offering. Out of total funding amount around USD 100 million will be used to build commerc...
Find MoreNovo Holdings optimistic about investments in life sciences Novo Holdings is planning to increase its investment in early & late stage biotechs. Its focus will be mainly in the U.S. and Europe. They are optimistic about the investment in life-science companies with their past experience. NMD gets USD 47 million...
Find MoreMerck and Eisai has entered into an Oncology Pact worth Up to USD 5.76 Billion Two major pharmaceutical companies (Merck & Eisai) has entered into a USD 5.76 Billion pact to develop and commercialize Lenvima (lenvatinib mesylate) both as a monotherapy and an in-combination therapy for treating multiple types of ...
Find MoreArbor Biotechnologies shining with new CRISPR enzyme Arbor Biotechnologies is shining with its new CRISPR enzyme and has successfully bagged USD 15.6 million in series A funding. The company has recently announced its first scientific discovery of a new enzyme, Cas13d, a CRISPR-Cas13 enzyme. It could offer advantag...
Find MoreM&A activity of Sanofi and Bioverative for rare blood diseases Sanofi has strengthened its position in hematology & speciality medicine by acquiring Bioverativ, Biogen hemophilia & blood disorders-focused company for USD 105 per share on March 8, 2018. This will increase Sanofi’s hemophilia portfolio for...
Find MoreAnthera’s Sollpura flops after phase 3 Anthera cut free it’s flopped late-arrange Lilly castoff Sollpura (liprotamase), and now looks for those feared "key choices". Sollpura was out-licensed by Lilly in 2014, and the written work had all the attributes of its failure, back in December 2016 when it posted the info...
Find MoreDermira pulling plug on acne drug after phase 3 failure Pharmaceutical company Dermira is pulling the plug on its acne drug (olumacostat glasaretil), after it failed to meet its primary endpoints in a pair of phase 3 trials. The drug was tested in patients aged nine and older with moderate to severe acne vulgaris. ...
Find MoreAcute Respiratory Distress Syndrome (ARDS) is a serious lung condition that causes low blood oxygen......
Find MoreThe coronavirus outbreak has affected thousands of people in at least 186 countries which has also a.....
Find MoreA rare glomerular kidney-scarring disease, Focal Segmental Glomerulosclerosis (FSGS) is a disease wi.....
Find MoreGene Therapy has shown tremendous growth in the past few years. The use of AAV (adeno-associated vir.....
Find MoreParoxysmal Nocturnal Hemoglobinuria (PNH) is a rare acquired disease that leads to the destruction o.....
Find MoreA degenerative disease, Exocrine Pancreatic Insufficiency (EPI), is a consequence of insufficient pr.....
Find MoreThe American Society of Clinical Oncology (ASCO) is one of the largest and most respected conferences in the field of oncology. Held annually, this conference brings together researchers, physicians, and other healthcare professionals from around the world to discuss the latest advances in cancer research, diagnosis, and treatment.